Traders Buy High Volume of Teladoc Health Call Options (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOCGet Free Report) was the recipient of some unusual options trading on Thursday. Traders purchased 61,931 call options on the company. This is an increase of approximately 377% compared to the typical daily volume of 12,988 call options.

Insider Activity at Teladoc Health

In other Teladoc Health news, Director Thomas Mckinley purchased 4,000 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was bought at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the acquisition, the director now owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. The trade was a 11.40 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Willem Waters sold 4,218 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total value of $30,200.88. Following the sale, the chief operating officer now owns 78,309 shares in the company, valued at $560,692.44. This trade represents a 5.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,051 shares of company stock valued at $143,565. 0.95% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently made changes to their positions in the business. Signaturefd LLC raised its position in shares of Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after purchasing an additional 1,715 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Teladoc Health in the second quarter valued at $29,000. Covestor Ltd boosted its position in shares of Teladoc Health by 58.1% in the first quarter. Covestor Ltd now owns 3,817 shares of the health services provider’s stock worth $57,000 after buying an additional 1,403 shares during the period. Blue Trust Inc. grew its holdings in shares of Teladoc Health by 84.5% during the third quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock valued at $40,000 after buying an additional 1,854 shares in the last quarter. Finally, Doheny Asset Management CA acquired a new position in Teladoc Health during the second quarter valued at $46,000. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Stock Performance

Shares of TDOC opened at $10.63 on Friday. The firm has a 50-day moving average price of $9.05 and a 200 day moving average price of $9.31. The firm has a market capitalization of $1.83 billion, a PE ratio of -1.84 and a beta of 0.90. Teladoc Health has a 52-week low of $6.76 and a 52-week high of $22.54. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOCGet Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The firm had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. On average, sell-side analysts anticipate that Teladoc Health will post -1.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TDOC. Truist Financial decreased their target price on Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a report on Friday, August 2nd. Piper Sandler decreased their target price on shares of Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. The Goldman Sachs Group assumed coverage on Teladoc Health in a research report on Friday, November 15th. They set a “buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price objective on shares of Teladoc Health in a report on Tuesday, August 20th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a report on Friday, November 1st. Fourteen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Teladoc Health presently has an average rating of “Hold” and a consensus price target of $12.08.

Check Out Our Latest Report on Teladoc Health

Teladoc Health Company Profile

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Featured Stories

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.